Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer. (PubMed, Eur Urol Oncol) - Sep 9, 2026 - "Antibody-drug conjugates (ADCs), particularly enfortumab vedotin (EV) in combination with pembrolizumab, have emerged as transformative treatments for advanced bladder cancer (BC). As such, assessing membranous Nectin-4 expression prior to EV therapy might be particularly relevant in postplatinum settings. Additionally, identifying alternative, chemotherapy-induced druggable vulnerabilities can inform more effective treatment strategies."
Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4 • TGFB1
|
|
Agata Suleja; Anna Koren; Bernhard Englinger; Christine Pirker; Christoph Nössing; Eva Compérat; Iris E Ertl; Isabella Prantl; Jule Schrimpf; Luis Rupp; Markus Eckstein; Oliver Baumfried; Paula Herek; Reinhard Grausenburger; Shahrokh F Shariat; Stefan Kubicek; Ursula Lemberger; Walter Berger
|